Liver Fibrosis Scan Tracks Disease Stage
A small single-center study links whole-liver Ga-68 FAPI PET uptake to worsening liver fibrosis stages.
Updated on Nov. 18, 2026 in Stroke

Researchers at the University of Wisconsin in Madison found that whole-liver Ga-68 FAPI PET uptake rose significantly as liver fibrosis progressed. The prospective study of 30 adults with known or suspected chronic liver disease compared PET results with clinical liver biopsies.
Why it matters
Current elastography-based methods are limited in detecting early-stage disease and distinguishing fibrosis from active inflammation. A noninvasive imaging approach that tracks fibrosis could help clinicians in Wisconsin and beyond monitor liver disease with fewer biopsies.
The study enrolled 30 adults, with 13 at F2 fibrosis, the largest group, and SUVL rose significantly across fibrosis stages (p = 0.012) with a Spearman correlation of rho = 0.57 (p = 0.0008). Larger multicenter trials needed to confirm these results are not described in the source.
The players
University of Wisconsin in Madison
A public research university whose institutions conduct extensive clinical and imaging research, including this study's authors.
The details
Patients received intravenous Ga-68 FAPI-46 and were imaged on a Signa PET/MR hybrid system, with liver data acquired 45 minutes after injection. Whole-liver uptake was normalized to lean body mass (SUVL) and compared against biopsy-confirmed fibrosis stages F0 through F4.
Timeline
45 minutes post-injection: PET data was acquired over the liver.
Tuesday, late afternoon: the study was presented at an RSNA session.
Health Landscape
Elastography has been the main noninvasive tool for staging liver fibrosis, but it struggles to catch early disease and to separate scarring from active inflammation. This FAPI PET study suggests molecular imaging could fill that gap, though it remains an early-stage, small-scale finding.
For people with chronic liver disease, a noninvasive scan that tracks fibrosis could one day reduce the need for repeated biopsies. The approach is still experimental, so it does not change current treatment or testing options today.
The takeaway
Noninvasive imaging that tracks liver scarring could eventually spare patients repeated biopsies, but larger studies are needed before it reaches routine care. Patients with chronic liver disease should keep discussing monitoring options with their own clinicians.
Further reading
Explore more stroke coverage in Wisconsin for related medical research context.










